132 related articles for article (PubMed ID: 37578465)
1. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
2. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
3. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
4. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway.
Jin G; Ma M; Yang C; Zhen L; Feng M
Thorac Cancer; 2023 Aug; 14(24):2493-2503. PubMed ID: 37423604
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
6. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
8. FOXA1/UBE2T Inhibits CD8
Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
Qu S; Jiao Z; Lu G; Yao B; Wang T; Rong W; Xu J; Fan T; Sun X; Yang R; Wang J; Yao Y; Xu G; Yan X; Wang T; Liang H; Zen K
Genome Biol; 2021 Apr; 22(1):104. PubMed ID: 33849634
[TBL] [Abstract][Full Text] [Related]
10. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
11. Solamargine improves the therapeutic efficacy of anti-PD-L1 in lung adenocarcinoma by inhibiting STAT1 activation.
Liu Q; Xu M; Qiu M; Yu J; Wang Q; Zhou Y; Lin Q; Cai X; Yang L; Zhao H; Zhao C; Xie X
Phytomedicine; 2024 Jun; 128():155538. PubMed ID: 38552432
[TBL] [Abstract][Full Text] [Related]
12. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.
Tong L; Shan M; Zou W; Liu X; Felsher DW; Wang J
Front Oncol; 2022; 12():904969. PubMed ID: 35978822
[TBL] [Abstract][Full Text] [Related]
13. The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
Zhu P; Kang G; Jiao Y; Gui C; Fan H; Li X; Jia Y; Zhang L; Ma X
Hum Cell; 2022 Jul; 35(4):1207-1218. PubMed ID: 35593989
[TBL] [Abstract][Full Text] [Related]
14. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
[TBL] [Abstract][Full Text] [Related]
17. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
18. NPM3 as an Unfavorable Prognostic Biomarker Involved in Oncogenic Pathways of Lung Adenocarcinoma
Chen L; Yang D; Huang F; Xu W; Luo X; Mei L; He Y
Comb Chem High Throughput Screen; 2024; 27(2):203-213. PubMed ID: 37114782
[TBL] [Abstract][Full Text] [Related]
19. CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis.
Gao C; Xu YJ; Qi L; Bao YF; Zhang L; Zheng L
Cell Biol Toxicol; 2022 Oct; 38(5):825-845. PubMed ID: 34018092
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
Huang J; Weng Q; Shi Y; Mao W; Zhao Z; Wu R; Ren J; Fang S; Lu C; Du Y; Ji J
FEBS Open Bio; 2020 Jun; 10(6):1065-1071. PubMed ID: 32237066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]